Aperture Bio Invited to Present at Antimicrobial Resistance World Congress

(Dallas, TX – 5/13/19) - www.Aperturebio.com – Aperture Bio announces it has been invited to present at the WORLD ANTIMICROBIAL RESISTENCE CONGRESS on November 7-8 in Washington, D.C. Aperture will present its RAPID-BTM in vitro diagnostic platform for the rapid detection of bacterial infections and antibiotic profiling, which could assist caregivers reduce the need for empirical overprescribing of antibiotics.

The event will host some +600 attendees from over 40 countries, including scientists, world health leaders, technology innovators and venture capitalists. According to its organizers: “The World Anti-Microbial Resistance Congress brings together all the stakeholders involved in developing new antimicrobial drugs and diagnostics. The event focusses on one of the most important challenges currently facing the global healthcare sector: tackling scientific and economic issues around antimicrobial resistance.”

In a statement from Aperture Bio’s president, David Potenza, “we are extremely honored to be recognized as an innovative technology and invited to present at such a prestigious and impactful conference. The opportunity to become part of a global initiative to potentially save millions of lives is a humbling opportunity for our emerging company.”

About the RAPID-BTM -

Utilizing highly customized and fully robotic next-gen flow cytometric technology (nFC), coupled with proprietary chemistry and customized platting, the RAPID-BTM platform can discriminate live uropathogen bacteria from those that are dead/damaged, as well as, normal urogenital contaminants, which could result in false positives and lead to unnecessary treatment.

Centered around a sensitive array of lasers, the system enumerates only viable bacteria and white blood cells within minutes and provides Antibiotic Predictive Profiling (APP) within hours. Specifically knowing which patients to treat and providing a rapid, categorical assessment of treatment options could both greatly reduce the risks for millions of patients being unnecessarily overexposed to antibiotics and save millions in healthcare costs.

The speed and accuracy of the test will reduce turn-around-times, with actionable results, from days to hours when compared to current screen, culture and reflexed Antibiotic Susceptibility Testing (AST). By rapidly isolating those patients that are negative vs. positive aids healthcare professionals to quickly and accurately identify not only those patients that may require further treatment, but equally as important, those that do not require antibiotic treatments.

The urgent need to reduce the overuse and misuse of antibiotics through empirical prescribing is at the forefront of the world’s public health agencies. The unintentional overuse and misuse of antibiotics is, in great part, due to the empirical over-prescribing in a partially “blind,” defensive response by caregivers as they await lab results. With reports suggesting that +/-90% of blood and +/-60% of urine cultures come back negative, the ability to accurately and rapid discriminate positive vs. negative patients within minutes for urine, and a few hours in blood, could significantly reduce this overuse and misuse, which is at the foundation of the antibiotic resistance pandemic.

In a statement from Matthew Gombrich, MD, M.S, Chief Medical Officer at Aperture Bio, “in an era of alarming rates of antibiotic resistance, the negative predictive value of what we have achieved cannot be overstated. Reducing the overuse and misuse of antibiotics through new technology like the RAPID-B could help save millions of lives and billions of dollars ...and should be in the hands of healthcare providers word-wide.”

About Aperture Bio – Aperture Bio is a privately held laboratory diagnostic company whose focus is to bring emerging technologies to market aimed at addressing antibiotic resistance and other world health issues. The company is currently seeking investors to further expand its product offering and the commercialization of its proprietary RAPID-BTM platform. For investment opportunities, please contact Mr. David Potenza dpotenza@aperturebio.com

Aperture Bio, LLC
20 Winter Sport Ln
Ste 150
Williston, VT 05495
David Potenza
President
dpotenza@aperturebio.com
214-707-8710

This release was published on openPR.